Pradeep Shrestha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Pradeep Shrestha has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Arthur H. Winter
Department of Chemistry Iowa State University Ames Iowa USA
3 shared publications - Martin J. Schnermann
Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, USA
3 shared publications - Andrew A. Beharry
Department of Chemical and Physical Sciences
1 shared publication Atreyee Mukhopadhyay
Department of Chemistry, Iowa State University, 1608 Gilman Hall, Ames, Iowa50010, United States
1 shared publicationConnor Wang
Chemical Biology Laboratory, Center for Cancer Research
1 shared publication- Connor Wang
National Institutes of Health
1 shared publication
Latest Publications
- 16 January 2026
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 37 (2) , 351-357
Fluorogenic Imaging Enables the Identification of Phosphoramidate Antibody–Drug Conjugate Linkers
Modular, tunable linker chemistries that are stable in circulation yet selectively cleaved are needed to realize the therapeutic potential of antibody-drug conjugates (ADCs). Near-infrared (NIR) fluorogenic imaging using norcyanine carbamate (CyBam) probes can quantitatively compare ADC linkers across in vitro and in vivo settings. A series of substituted CyBams modified with phosphoramidates, peptides, and control triggers were conjugated to EGFR-targeting monoclonal antibody (mAb) panitumumab. Imaging in cellular and in vivo settings reveals the potential for novel phosphoramidate linkers, showing selective cellular activation, excellent tumor localization, and reduced liver signal compared to conventional proteolytic linkers. Guided by these imaging results, monomethyl auristatin E (MMAE) conjugates bearing the new linkers were prepared and displayed picomolar potency, receptor-dependent activity, and promising in vivo tumor growth inhibition. In total, these studies demonstrate that quantitative fluorogenic imaging can enable the discovery and prioritization of new ADC linkers.
- 16 January 2026
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 37 (2) , 351-357
Fluorogenic Imaging Enables the Identification of Phosphoramidate Antibody–Drug Conjugate Linkers
Modular, tunable linker chemistries that are stable in circulation yet selectively cleaved are needed to realize the therapeutic potential of antibody-drug conjugates (ADCs). Near-infrared (NIR) fluorogenic imaging using norcyanine carbamate (CyBam) probes can quantitatively compare ADC linkers across in vitro and in vivo settings. A series of substituted CyBams modified with phosphoramidates, peptides, and control triggers were conjugated to EGFR-targeting monoclonal antibody (mAb) panitumumab. Imaging in cellular and in vivo settings reveals the potential for novel phosphoramidate linkers, showing selective cellular activation, excellent tumor localization, and reduced liver signal compared to conventional proteolytic linkers. Guided by these imaging results, monomethyl auristatin E (MMAE) conjugates bearing the new linkers were prepared and displayed picomolar potency, receptor-dependent activity, and promising in vivo tumor growth inhibition. In total, these studies demonstrate that quantitative fluorogenic imaging can enable the discovery and prioritization of new ADC linkers.
- Open Access
- 22 December 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Fluorogenic Imaging Enables the Identification of Phosphoramidate Antibody–Drug Conjugate Linkers
Modular, tunable linker chemistries that are stable in circulation yet selectively cleaved are needed to realize the therapeutic potential of antibody drug conjugates (ADCs). Near-infrared (NIR) fluorogenic imaging using norcyanine carbamate (CyBam) probes can quantitatively compare ADC linkers across in vitro and in vivo settings. A series of substituted CyBams modified with phosphoramidates, peptide, and control triggers were conjugated to the EGFR-targeting monoclonal antibody (mAb) panitumumab. Imaging in cellular and in vivo settings reveal the potential for novel phosphoramidate linkers, showing selective cellular activation, excellent tumor-localization, and reduced liver signal compared to conventional proteolytic linkers. Guided by these imaging results, monomethyl auristatin E (MMAE) conjugates bearing the new linkers were prepared and display picomolar potency, receptor dependent activity and promising in vivo tumor growth inhibition. In total, these studies demonstrate that quantitative fluorogenic imaging can enable the discovery and prioritization of new ADC linkers.
- 22 December 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessFluorogenic Imaging Enables the Identification of Phosphoramidate Antibody–Drug Conjugate Linkers
Modular, tunable linker chemistries that are stable in circulation yet selectively cleaved are needed to realize the therapeutic potential of antibody drug conjugates (ADCs). Near-infrared (NIR) fluorogenic imaging using norcyanine carbamate (CyBam) probes can quantitatively compare ADC linkers across in vitro and in vivo settings. A series of substituted CyBams modified with phosphoramidates, peptide, and control triggers were conjugated to the EGFR-targeting monoclonal antibody (mAb) panitumumab. Imaging in cellular and in vivo settings reveal the potential for novel phosphoramidate linkers, showing selective cellular activation, excellent tumor-localization, and reduced liver signal compared to conventional proteolytic linkers. Guided by these imaging results, monomethyl auristatin E (MMAE) conjugates bearing the new linkers were prepared and display picomolar potency, receptor dependent activity and promising in vivo tumor growth inhibition. In total, these studies demonstrate that quantitative fluorogenic imaging can enable the discovery and prioritization of new ADC linkers.
- Open Access
- 7 November 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Tracking the Fate of Therapeutic Proteins Using Ratiometric Imaging of Responsive Shortwave Infrared Probes
Monoclonal antibodies (mAbs) are essential agents for cancer treatment and diagnosis. Advanced optical imaging strategies have the potential to address specific questions regarding their complex in vivo life cycle. This study presents responsive shortwave infrared (SWIR) probes and an associated imaging scheme to assess mAb biodistribution, cellular uptake, and proteolysis. Specifically, we identify a Pegylated benzo-fused norcyanine derivative (Benz-NorCy7) that is activated in acidic environments and can be appended to mAbs without significant changes in optical properties. As a mAb conjugate, this agent shows high tumor specificity in a longitudinal imaging study in a murine model. To enable independent tracking of mAb uptake and lysosomal uptake and retention, a two-color ratiometric imaging strategy was employed using an "always-ON" heptamethine cyanine dye (ex = 785 nm) and the pH-responsive Benz-NorCy7 (ex = 890 nm). To assess proteolytic catabolism, we append a cleavable carbamate to Benz-NorCy7 to create turn-ON probes. These agents facilitate the compari-son of two common peptide linkers and provide insights into their in vivo properties. Overall, these studies provide a strate-gy to assess the fate of protein-based therapeutics using optical imaging in the SWIR range.
- 7 November 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessTracking the Fate of Therapeutic Proteins Using Ratiometric Imaging of Responsive Shortwave Infrared Probes
Monoclonal antibodies (mAbs) are essential agents for cancer treatment and diagnosis. Advanced optical imaging strategies have the potential to address specific questions regarding their complex in vivo life cycle. This study presents responsive shortwave infrared (SWIR) probes and an associated imaging scheme to assess mAb biodistribution, cellular uptake, and proteolysis. Specifically, we identify a Pegylated benzo-fused norcyanine derivative (Benz-NorCy7) that is activated in acidic environments and can be appended to mAbs without significant changes in optical properties. As a mAb conjugate, this agent shows high tumor specificity in a longitudinal imaging study in a murine model. To enable independent tracking of mAb uptake and lysosomal uptake and retention, a two-color ratiometric imaging strategy was employed using an "always-ON" heptamethine cyanine dye (ex = 785 nm) and the pH-responsive Benz-NorCy7 (ex = 890 nm). To assess proteolytic catabolism, we append a cleavable carbamate to Benz-NorCy7 to create turn-ON probes. These agents facilitate the compari-son of two common peptide linkers and provide insights into their in vivo properties. Overall, these studies provide a strate-gy to assess the fate of protein-based therapeutics using optical imaging in the SWIR range.
- Top Cited Papers
- 3 August 2023
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 145 (32) , 17497-17514
meso-Methyl BODIPY Photocages: Mechanisms, Photochemical Properties, and Applications
meso-methyl BODIPY photocages have recently emerged as an exciting new class of photoremovable protecting groups (PPGs) that release leaving groups upon absorption of visible to near-infrared light. In this Perspective, we summarize the development of these PPGs and highlight their critical photochemical properties and applications. We discuss the absorption properties of the BODIPY PPGs, structure-photoreactivity studies, insights into the photoreaction mechanism, the scope of functional groups that can be caged, the chemical synthesis of these structures, and how substituents can alter the water solubility of the PPG and direct the PPG into specific subcellular compartments. Applications that exploit the unique optical and photochemical properties of BODIPY PPGs are also discussed, from wavelength-selective photoactivation to biological studies to photoresponsive organic materials and photomedicine.
- 3 August 2023
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 145 (32) , 17497-17514
Top Cited Papersmeso-Methyl BODIPY Photocages: Mechanisms, Photochemical Properties, and Applications
meso-methyl BODIPY photocages have recently emerged as an exciting new class of photoremovable protecting groups (PPGs) that release leaving groups upon absorption of visible to near-infrared light. In this Perspective, we summarize the development of these PPGs and highlight their critical photochemical properties and applications. We discuss the absorption properties of the BODIPY PPGs, structure-photoreactivity studies, insights into the photoreaction mechanism, the scope of functional groups that can be caged, the chemical synthesis of these structures, and how substituents can alter the water solubility of the PPG and direct the PPG into specific subcellular compartments. Applications that exploit the unique optical and photochemical properties of BODIPY PPGs are also discussed, from wavelength-selective photoactivation to biological studies to photoresponsive organic materials and photomedicine.
- 8 December 2022
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (24) , 16679-16694
Photocaged DNA-Binding Photosensitizer Enables Photocontrol of Nuclear Entry for Dual-Targeted Photodynamic Therapy
Photodynamic therapy (PDT) is a clinically approved cancer treatment that requires a photosensitizer (PS), light, and molecular oxygen─a combination which produces reactive oxygen species (ROS) that can induce cancer cell death. To enhance the efficacy of PDT, dual-targeted strategies have been explored where two photosensitizers are administered and localize to different subcellular organelles. To date, a single small-molecule conjugate for dual-targeted PDT with light-controlled nuclear localization has not been achieved. We designed a probe composed of a DNA-binding PS (Br-DAPI) and a photosensitizing photocage (WinterGreen). Illumination with 480 nm light removes WinterGreen from the conjugate and produces singlet oxygen mainly in the cytosol, while Br-DAPI localizes to nuclei, binds DNA, and produces ROS using one- or two-photon illumination. We observe synergistic photocytotoxicity in MCF7 breast cancer cells, and a reduction in size of three-dimensional (3D) tumor spheroids, demonstrating that nuclear/cytosolic photosensitization using a single agent can enhance PDT efficacy.
- 8 December 2022
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (24) , 16679-16694
Photocaged DNA-Binding Photosensitizer Enables Photocontrol of Nuclear Entry for Dual-Targeted Photodynamic Therapy
Photodynamic therapy (PDT) is a clinically approved cancer treatment that requires a photosensitizer (PS), light, and molecular oxygen─a combination which produces reactive oxygen species (ROS) that can induce cancer cell death. To enhance the efficacy of PDT, dual-targeted strategies have been explored where two photosensitizers are administered and localize to different subcellular organelles. To date, a single small-molecule conjugate for dual-targeted PDT with light-controlled nuclear localization has not been achieved. We designed a probe composed of a DNA-binding PS (Br-DAPI) and a photosensitizing photocage (WinterGreen). Illumination with 480 nm light removes WinterGreen from the conjugate and produces singlet oxygen mainly in the cytosol, while Br-DAPI localizes to nuclei, binds DNA, and produces ROS using one- or two-photon illumination. We observe synergistic photocytotoxicity in MCF7 breast cancer cells, and a reduction in size of three-dimensional (3D) tumor spheroids, demonstrating that nuclear/cytosolic photosensitization using a single agent can enhance PDT efficacy.
- 18 October 2022
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 87 (21) , 14334-14341
Efficiency of Functional Group Caging with Second-Generation Green- and Red-Light-Labile BODIPY Photoremovable Protecting Groups
BODIPY-based photocages release substrates by excitation with wavelengths in the visible to near-IR regions. The recent development of more efficient BODIPY photocages spurred us to evaluate the scope and efficiency of these second-generation boron-methylated green-light and red-light-absorbing BODIPY photocages. Here, we show that these more photosensitive photocages release amine, alcohol, phenol, phosphate, halides, and carboxylic acid derivatives with much higher quantum yields than first-generation BODIPY photocages and excellent chemical yields. Chemical yields are near-quantitative for the release of all functional groups except the photorelease of amines, which react with concomitantly photogenerated singlet oxygen. In these cases, high chemical yields for photoreleased amines are restored by irradiation under an inert atmosphere. The photorelease quantum yield has a weak relationship with the leaving group pKa of the green-absorbing BODIPY photocages but little relationship with the red-absorbing derivatives, suggesting that factors other than leaving group quality impact the quantum yield. For the photorelease of alcohols, in all cases a carbonate linker (that loses CO2 upon photorelease) significantly increases both the quantum yield and the chemical yield compared to those for direct photorelease via the ether.
- 18 October 2022
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 87 (21) , 14334-14341
Efficiency of Functional Group Caging with Second-Generation Green- and Red-Light-Labile BODIPY Photoremovable Protecting Groups
BODIPY-based photocages release substrates by excitation with wavelengths in the visible to near-IR regions. The recent development of more efficient BODIPY photocages spurred us to evaluate the scope and efficiency of these second-generation boron-methylated green-light and red-light-absorbing BODIPY photocages. Here, we show that these more photosensitive photocages release amine, alcohol, phenol, phosphate, halides, and carboxylic acid derivatives with much higher quantum yields than first-generation BODIPY photocages and excellent chemical yields. Chemical yields are near-quantitative for the release of all functional groups except the photorelease of amines, which react with concomitantly photogenerated singlet oxygen. In these cases, high chemical yields for photoreleased amines are restored by irradiation under an inert atmosphere. The photorelease quantum yield has a weak relationship with the leaving group pKa of the green-absorbing BODIPY photocages but little relationship with the red-absorbing derivatives, suggesting that factors other than leaving group quality impact the quantum yield. For the photorelease of alcohols, in all cases a carbonate linker (that loses CO2 upon photorelease) significantly increases both the quantum yield and the chemical yield compared to those for direct photorelease via the ether.